Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria fix for obesity skin woes?

NCT ID NCT07184905

Disease control Sponsor: Shenzhen People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether taking a daily probiotic called Bifidobacterium longum for one month could improve skin barrier damage in people with obesity. 140 participants took either the active probiotic or an inactive placebo. The researchers measured skin water loss and checked gut and skin samples to see if the probiotic helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bifidobacterium longum (a probiotic)
What this could lead to
If it works, this could point toward a simple probiotic supplement to help repair skin damage caused by obesity.
What could go wrong
This is a small, early-stage trial with only 140 people. The results may not apply to everyone, and the effect on skin might be small or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Sep 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * 1\. Meets 2020 WHO BMI classification: * a. Normal weight (18.5-24.9 kg/m²) * b. Overweight (25-29.9 kg/m²) * c. Obesity (≥30 kg/m²) * 2\. Presence of skin barrier impairment (e.g., dryness, erythema, desquamation, or itching) * 3\. Age 18-40 years * 4\. Generally good health (no active systemic diseases) * 5\. Able and willing to provide written informed consent * 6\. No use of oral/topical medications or probiotics within 6 months prior * 7\. No active skin disease or traumatic skin lesions Exclusion Criteria : * 1\. Known allergy or hypersensitivity to probiotics, placebo, or investigational product * 2\. Active skin disease (e.g., psoriasis, eczema, infection) requiring treatment * 3\. Severe medical conditions: * a. Cardiopulmonary disease (NYHA class III/IV) * b. Uncontrolled diabetes (HbA1c \>9%) * c. Autoimmune disorders * 4\. Pregnant or breastfeeding women * 5\. Any condition that may interfere with protocol compliance (per investigator judgement), including: * a. Inability to understand study procedures * b. History of poor clinical trial adherence * 6\. Concurrent participation in other interventional trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Microbial colonization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Microbial colonization Skin barrier to water loss

Contacts and locations

Locations

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, 518020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.